Journal of Neuro-Oncology

, Volume 75, Issue 2, pp 189–193 | Cite as

Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients

  • Gokhan OzyigitEmail author
  • Cem Onal
  • Murat Gurkaynak
  • Figen Soylemezoglu
  • Faruk Zorlu
Clinical Study


We retrospectively evaluate the prognostic factors affecting the local control, survival and the potential role of chemotherapy in the management of patients with oligodendroglioma. The medical records of 88 patients treated by postoperative external beam radiotherapy ± chemotherapy at our institution between December 1993 and December 2002 were analyzed. Nine patients (10%) were treated with an accelerated fractionation scheme, while 79 patients were treated with conventional doses. The median RT dose was 54.8 ± 2.58 Gy for low-grade tumors, and 58.7 ± 2.46 Gy for high-grade tumors. PCV chemotherapy regimen was given to 18 patients; temozolamide was administered in three patients. Chemotherapy was not given concomitantly in any patients. The median follow-up was 56 months (range 7–134 months). The 5-year overall and progression-free survival rates for entire group were 86% and 79%, respectively. Patients with epilepsy at presentation had better 5-year overall survival (93% vs. 74%, P=0.04). High grade tumors had significantly lower overall survival rate. Age, presence of motor deficit at diagnosis and histological grade were found have a significant impact on progression-free survival. The 5-year overall and progression free survival rates of patients with high-grade tumors were 69%, 51% and 74%, 68% for chemotherapy and no-chemotherapy group, respectively (P=0.9 for OS, P=0.3 for PFS). In multivariate analysis no significant factor affecting the overall survival and progression-free survival was found. Chemotherapy given after postoperative radiotherapy in patients with oligodendroglioma did not improve survival in this retrospective study.

Key words

chemotherapy oligodendroglioma radiotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Daumas-Duport, C, Tucker, ML, Kolles, H,  et al. 1997Oligodendrogliomas Part II: a new grading system based on morphological and imaging criteriaJ Neurooncol346178CrossRefPubMedGoogle Scholar
  2. 2.
    Mason, WP, Krol, GS, DeAngelis, LM 1996Low-grade oligodendroglioma responds to chemotherapyNeurology46203207PubMedGoogle Scholar
  3. 3.
    Coons, SW, Johnson, PC, Scheithauer, BW,  et al. 1997Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomasCancer7913811393CrossRefPubMedGoogle Scholar
  4. 4.
    Engelhard, HH, Stelea, A, Cochran, EJ 2002Oligodendroglioma: pathology and molecular biologySurg Neurol581111172002discussion 117CrossRefPubMedGoogle Scholar
  5. 5.
    Jukich, PJ, McCarthy, BJ, Surawicz, TS,  et al. 2001Trends in incidence of primary brain tumors in the United States, 1985–1994Neuro-oncology3141151CrossRefPubMedGoogle Scholar
  6. 6.
    Fortin, D, Macdonald, DR, Stitt, L, Cairncross, JG 2001PCV for oligodendroglial tumors: in search of prognostic factors for response and survivalCan J Neurol Sci28215223PubMedGoogle Scholar
  7. 7.
    Kros, JM, Pieterman, H, Eden, CG,  et al. 1994Oligodendroglioma: the Rotterdam–Dijkzigt experienceNeurosurgery349599661994discussion 966PubMedGoogle Scholar
  8. 8.
    Shaw, EG, Scheithauer, BW, O’Fallon, JR,  et al. 1992Oligodendrogliomas: the Mayo Clinic experienceJ Neurosurg76428434PubMedGoogle Scholar
  9. 9.
    Celli, P, Nofrone, I, Palma, L,  et al. 1994Cerebral oligodendroglioma: prognostic factors and life historyNeurosurgery35101810341994discussion 1034-1015PubMedGoogle Scholar
  10. 10.
    Bouffet, E, Jouvet, A, Thiesse, P,  et al. 1998Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatmentBr J Neurosurg12217222CrossRefPubMedGoogle Scholar
  11. 11.
    Bent, MJ, Kros, JM, Heimans, JJ,  et al. 1998Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy Dutch Neuro-oncology GroupNeurology5111401145PubMedGoogle Scholar
  12. 12.
    Dehghani, F, Schachenmayr, W, Laun, A,  et al. 1998Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 casesActa Neuropathol (Berl)95493504CrossRefGoogle Scholar
  13. 13.
    Shimizu, KT, Tran, LM, Mark, RJ,  et al. 1993Management of oligodendrogliomasRadiology186569572PubMedGoogle Scholar
  14. 14.
    Allam, A, Radwi, A, El Weshi, A,  et al. 2000Oligodendroglioma: an analysis of prognostic factors and treatment resultsAm J Clin Oncol23170175CrossRefPubMedGoogle Scholar
  15. 15.
    Gannett, DE, Wisbeck, WM, Silbergeld, DL,  et al. 1994The role of postoperative irradiation in the treatment of oligodendrogliomaInt J Radiat Oncol Biol Phys30567573PubMedGoogle Scholar
  16. 16.
    Wallner, KE, Gonzales, M, Sheline, GE 1988Treatment of oligodendrogliomas with or without postoperative irradiationJ Neurosurg68684688PubMedGoogle Scholar
  17. 17.
    Olson, JD, Riedel, E, DeAngelis, LM 2000Long-term outcome of low-grade oligodendroglioma and mixed gliomaNeurology5414421448PubMedGoogle Scholar
  18. 18.
    Allison, RR, Schulsinger, A, Vongtama, V,  et al. 1997Radiation and chemotherapy improve outcome in oligodendrogliomaInt J Radiat Oncol Biol Phys37399403CrossRefPubMedGoogle Scholar
  19. 19.
    Jeremic, B, Shibamoto, Y, Grujicic, D,  et al. 1998Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma. A phase II studyRadiother Oncol494954CrossRefPubMedGoogle Scholar
  20. 20.
    Cairncross, JG 1994Aggressive oligodendroglioma: a chemosensitive tumorRecent Results Cancer Res135127133PubMedGoogle Scholar
  21. 21.
    Eyre, HJ, Crowley, JJ, Townsend, JJ,  et al. 1993A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group studyJ Neurosurg78909914PubMedGoogle Scholar
  22. 22.
    Cairncross, JG, Macdonald, DR 1988Successful chemotherapy for recurrent malignant oligodendrogliomaAnn Neurol23360364CrossRefPubMedGoogle Scholar
  23. 23.
    Cairncross, JG, Ueki, K, Zlatescu, MC,  et al. 1998Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomasJ Natl Cancer Inst9014731479CrossRefPubMedGoogle Scholar
  24. 24.
    Bent, MJ, Keime-Guibert, F, Brandes, AA,  et al. 2001Temozolomide chemotherapy in recurrent oligodendrogliomaNeurology57340342PubMedGoogle Scholar
  25. 25.
    Chinot, OL, Honore, S, Dufour, H,  et al. 2001Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapyJ Clin Oncol1924492455PubMedGoogle Scholar
  26. 26.
    Leighton, C, Fisher, B, Bauman, G,  et al. 1997Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiationJ Clin Oncol1512941301PubMedGoogle Scholar
  27. 27.
    Henderson, KH, Shaw, EG 2001Randomized trials of radiation therapy in adult low-grade gliomasSemin Radiat Oncol11145151CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Gokhan Ozyigit
    • 1
    Email author
  • Cem Onal
    • 1
  • Murat Gurkaynak
    • 1
  • Figen Soylemezoglu
    • 2
  • Faruk Zorlu
    • 1
  1. 1.Department of Radiation Oncology, Faculty of MedicineHacettepe UniversityAnkaraTurkey
  2. 2.Department of Pathology, Faculty of MedicineHacettepe UniversityAnkaraTurkey

Personalised recommendations